Published in Vaccine Weekly, January 4th, 2006
According to a report from Canada, "TLR ligands that mimic pathogen associated molecular pat terns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as imiquimod and resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODNs) that bind to TLR9."
"This study compared CpG ODNs and R-848 for their potential use as vaccine adjuvants and to determined whether there are additive or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.